F S&P 500
5,540.75 +3.75 (+0.07%) F Dow Jones
39,513.00 -13.00 (-0.03%) F Nasdaq
19,999.75 +27.50 (+0.14%) E-mini Russell 2000 Index Futur
2,044.60 -0.30 (-0.01%) Petróleo
81.01 +0.18 (+0.22%) Oro
2,325.50 -5.30 (-0.23%)
Photocure ASA (PHCUF)
Photocure ASA
Hoffsveien 4
Oslo 0275
Norway
47 22 06 22 10
https://www.photocure.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 102
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Daniel Schneider | President & CEO | N/D | N/D | N/D |
| Mr. Erik Dahl | Chief Financial Officer | N/D | N/D | 1957 |
| Mr. David Moskowitz | Head of Investor Relations | N/D | N/D | N/D |
| Anja Gossens-von der Heidt | Head of Global Human Resources | N/D | N/D | N/D |
| Dr. Anders Neijber M.D. | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D | N/D | N/D | N/D |
| Mr. Tolv Hillestad | Group Controller | N/D | N/D | N/D |
Descripción
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Gestión corporativa
La calificación ISS Governance QuickScore de Photocure ASA a partir del 1 de junio de 2024 es 6. Las puntuaciones principales son Auditoría: 1; Junta: 4; Derechos del accionista: 4; Compensación: 8.
